1147014-68-3 Usage
Uses
Used in Medicinal Chemistry:
7H-Pyrrolo[2,3-d]pyriMidine, 4-[2-(triMethylsilyl)ethynyl]is employed as a crucial building block for the synthesis of biologically active compounds, contributing to the development of new pharmaceuticals. Its triMethylsilyl group enhances the molecule's stability and reactivity, facilitating the creation of diverse medicinal agents.
Used in Drug Discovery:
In the realm of drug discovery, 7H-Pyrrolo[2,3-d]pyriMidine, 4-[2-(triMethylsilyl)ethynyl]serves as a valuable intermediate, aiding researchers in the identification and development of potential drug candidates. Its unique structural features and enhanced reactivity make it a preferred choice for constructing novel therapeutic agents.
Used in Pharmaceutical Industry:
7H-Pyrrolo[2,3-d]pyriMidine, 4-[2-(triMethylsilyl)ethynyl]is used as a key intermediate in the pharmaceutical industry for the preparation of various pharmaceuticals. Its role in enhancing the stability and reactivity of molecules makes it instrumental in the formulation of effective and stable drug products.
Used in Agrochemical Development:
7H-Pyrrolo[2,3-d]pyriMidine, 4-[2-(triMethylsilyl)ethynyl]also finds application in the agrochemical sector, where it is utilized in the development of new agrochemical products. The triMethylsilyl group's ability to improve the molecule's stability and reactivity is particularly beneficial in creating agrochemicals with enhanced performance and longer shelf life.
Check Digit Verification of cas no
The CAS Registry Mumber 1147014-68-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,7,0,1 and 4 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1147014-68:
(9*1)+(8*1)+(7*4)+(6*7)+(5*0)+(4*1)+(3*4)+(2*6)+(1*8)=123
123 % 10 = 3
So 1147014-68-3 is a valid CAS Registry Number.
1147014-68-3Relevant articles and documents
Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition
Gehringer, Matthias,Forster, Michael,Laufer, Stefan A.
supporting information, p. 5 - 10 (2015/01/30)
A solution-phase parallel synthesis of triazole-derived ruxolitinib analogues was developed in the current study. The method employs copper-catalyzed azide-alkyne cycloaddition to build up the central triazole template. Product isolation by precipitation
PROTEIN KINASE INHIBITORS AND USE THEREOF
-
Page/Page column 26, (2011/11/30)
Disclosed are compounds according to Formula I: wherein the variables are described herein.
PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME
-
Page/Page column 53, (2009/05/30)
Provided herein are pyrrolopyrimide alkynyl compounds, and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.
